The Probiotics, Prebiotics & Synbiotics track at the Global Gastroenterology, Liver Diseases & Hepatology Conference & Industry Expo focuses on the rapidly evolving science of the gut microbiome and its role in digestive, liver, and systemic health. This session brings together clinicians, microbiome researchers, nutrition scientists, industry leaders, and investors to explore evidence-based applications and next-generation innovations.
The program will cover mechanisms of action, clinical efficacy, strain specificity, personalized nutrition, and therapeutic modulation of the microbiome in gastrointestinal and hepatological disorders. Special emphasis will be placed on translational research, regulatory frameworks, product development, and commercialization strategies.
With strong attention to innovation, investment, and industry partnerships, this platform enables collaboration between academia, pharmaceutical and nutraceutical companies, biotech startups, food technology firms, and healthcare providers. Attendees will gain insights into emerging trends, market opportunities, and real-world clinical integration of microbiome-based solutions.
Join global experts to shape the future of microbiome science—where research, clinical practice, and industry converge to advance patient care and sustainable healthcare innovation.
Sub Topics: Gut microbiome fundamentals, Probiotics in gastrointestinal health, Prebiotics and dietary fibers, Synbiotics: concept and clinical use, Strain-specific probiotic efficacy, Microbiome and digestive disorders, Role of probiotics in IBD, Probiotics in IBS management, Gut–liver axis and microbiota, Microbiome in NAFLD and NASH, Probiotics in liver cirrhosis, Hepatic encephalopathy and microbiome, Microbiome and immune modulation, Pediatric applications of probiotics, Microbiome in metabolic disorders, Personalized microbiome-based therapies, Advances in synbiotic formulations, Next-generation probiotics, Postbiotics and emerging concepts, Probiotics and antibiotic-associated diarrhea, Microbiome and colorectal cancer prevention, Role of prebiotics in gut health, Microbiota and gut barrier function, Probiotics in H. pylori management, Microbiome and bile acid metabolism, Regulatory challenges in probiotic products, Clinical trial design for microbiome studies, Safety and quality control of probiotics, Probiotics in functional GI disorders, Microbiome and aging, Digital tools in microbiome research, AI-driven microbiome analysis, Industrial scale production of probiotics, Investment trends in microbiome startups, Commercialization of microbiome therapeutics, Nutraceutical innovations in gut health, Food technology and functional foods, Microbiome-based diagnostics, Synbiotics in clinical nutrition, Microbiome modulation strategies, Role of diet in shaping microbiota, Global guidelines for probiotic use, Ethics in microbiome research, Microbiome and mental health, Gut–brain axis interactions, Public health impact of probiotics, Future directions in microbiome science
Keynote Points:
High global burden of acute and infectious diarrheal diseases
Strong and consistent demand for ORS, zinc, and supportive therapies
Expansion opportunities in pediatric, travel, and emergency care segments
Growth of flavored, ready-to-drink, and fortified ORS formulations
Integration with probiotics and gut-health products
Public–private partnerships in national and global health programs
Distribution strength and affordability as key market drivers
Benefits:
Large-volume, high-frequency product demand ensuring steady revenue
Strong presence in public health tenders and mass-distribution programs
High brand visibility and trust in essential healthcare products
Opportunities for market expansion in emerging and high-burden regions
Cross-selling potential with nutrition, pediatric, and preventive care products
Long-term sustainability supported by ongoing global healthcare needs
WhatsApp: https://wa.me/+971551792927
Email: info-ucg@utilitarianconferences.com